A5052275871- Infective Endocarditis Diagnosis and Management
- Cardiac Valve Diseases and Treatments
- Cardiac Structural Anomalies and Repair
- Aortic Disease and Treatment Approaches
- Mechanical Circulatory Support Devices
- Cardiac Arrest and Resuscitation
- Cardiac tumors and thrombi
- Cardiac, Anesthesia and Surgical Outcomes
- Orthopedic Infections and Treatments
- Infectious Aortic and Vascular Conditions
- Cardiac and Coronary Surgery Techniques
- Cardiac pacing and defibrillation studies
- Sarcoma Diagnosis and Treatment
- Congenital Heart Disease Studies
- Pulmonary Hypertension Research and Treatments
- Aortic aneurysm repair treatments
- Streptococcal Infections and Treatments
- Atrial Fibrillation Management and Outcomes
- Antimicrobial Resistance in Staphylococcus
- Cardiovascular Function and Risk Factors
- Peptidase Inhibition and Analysis
- Vascular Tumors and Angiosarcomas
- Surgical Simulation and Training
- Lipoproteins and Cardiovascular Health
- Coronary Artery Anomalies
University Hospital in Halle
2024
West German Heart and Vascular Center Essen
2021-2023
University of Duisburg-Essen
2021-2023
Essen University Hospital
2020-2023
Deutsches Herzzentrum München
2022
University Hospital Cologne
2021
Klinikum Oldenburg
2017-2020
Heidelberg University
2017-2020
Carl von Ossietzky Universität Oldenburg
2018-2019
Creative Research Enterprises (United States)
2018
Abstract Background Mitral valve repair (MVRe) is considered to have a superior outcome compared replacement (MVRp) in patients with mitral regurgitation (MVR). It was the aim of study analyse clinical results and identify risk factors for short long-term mortality. Methods In retrospective single-center analysis, undergoing an isolated procedure from June 2010 December 2016 were identified. These subsequently homogenized using 10 baseline characteristics propensity-score matching....
BACKGROUND The aim of this study was to investigate the clinical presentation, operative data, and early late outcomes a large patient cohort undergoing surgical treatment for cardiac tumors in our institution. MATERIAL AND METHODS A total 181 patients underwent surgery because suspected tumor institution between 1998 2016. In 162 cases, diagnosis confirmed postoperatively these were included study. Preoperative baseline characteristics, postoperative long-term analyzed. RESULTS Mean age at...
Background: Coronary artery disease is a major cause of death globally. Minimally invasive direct coronary bypass (MIDCAB), using small left anterior thoracotomy, aims to provide less alternative traditional procedures, potentially improving patient outcomes with reduced recovery times. Methods: This retrospective, non-randomized study analyzed 310 patients who underwent MIDCAB between July 1999 and April 2022. Data were collected on demographics, clinical characteristics, operative...
Abstract We present a comparison between three left ventricular assist devices (LVADs): HeartWare (HVAD) (HeartWare International Inc., Framingham, MA, USA), HeartMate II (HMII) and III (HMIII) (Thoratec Corp., Pleasanton, CA, USA). To our knowledge, no study to date has aimed at placing these in juxtaposition. Between June 2007 2017, 108 consecutive patients received HMII, n = 77 (71.3%), HVAD, 14 (13%), or HM III, 17 (15.7%), for end‐stage heart failure. Mean age was 63.8 ± 11.2 years...
Introduction Transcatheter aortic valve implantation (TAVI) techniques are increasingly being adopted into clinical routine for various risk groups. Coronary artery disease (CAD) is seen in up to 75% of patients with severe stenosis (AS) presenting typical angina pectoris. Due high mortality rates and procedural complications these patients, a hybrid concept simultaneous transaortic TAVI off-pump coronary bypass (OPCAB) can be feasible treatment option. Methods Between April 2014 July 2020,...
The objectives of this study was to investigate if concomitant tricuspid valve repair in patients undergoing continuous flow left ventricular assist device (LVAD) implantation has an impact on the outcome regarding survival and adverse events.Between June 2007 February 2018, 124 consecutive received HeartMate II (HMII) [74 (59.7%)] HeartWare (HVAD) [16 (12.9%)], or III (HM III) [34 (27.4%)] for end-stage heart failure. Mean age 63.5±10.9 years. Two 18-patient groups were identified; with...
BACKGROUND We reviewed our clinical experience with cardiac papillary fibroelastoma from 2005 to 2017. The objective of this study was investigate the and operative data, as well early survival rate immediate postoperative complications. MATERIAL AND METHODS performed a retrospective analysis 11 patients (eight males three females) who underwent resection in institution. RESULTS Mean age at tumor diagnosis 60±14 years. mean dimension 14±11 mm. most common symptoms were dyspnea, palpitation,...
Minimally invasive mitral valve surgery (MVS) via right mini-thoracotomy has recently attracted a lot of attention. MVS shows postoperative results that are comparable to those conventional through the median sternotomy as per various earlier studies.Between 2000 and 2016, total 669 isolated procedures for regurgitation were performed. A propensity score-matched analysis was generated elimination differences in relevant preoperative risk factors between cohorts included 227 patient pairs....
MitraClip implantation is a valid interventional option that offers acceptable short-term results. Surgery after failed procedures remains challenging in high-risk patients. The data on these cases are limited by the small sample numbers.The aim of our study to show, mitral valve surgery could be possible and more advantageous, even patients.Between 2010 2016, nine patients underwent therapy at institution.The patients' ages ranged from 19 75 years (mean: 61.2 ± 19.6 years). median interval...
With the rapid development of mechanical circulatory support technologies, patients presenting with cardiogenic shock have gained access to various treatment opportunities which were not until recently available. The Impella® pump (Abiomed, Danvers, USA) is a minimally invasive device provides excellent left ventricular unloading and full support. aim study was review our center's experience analyze major adverse events associated device.From January 2020 2022, total 32 underwent...
Surgical aortic valve replacement remains the gold standard of treatment in patients with active infective endocarditis. Such procedures tend to carry a significantly higher operative risk when compared conventional for non-infective disease. Sutureless (SU-AVR) has been introduced into cardiac surgery allow simpler implementation minimally invasive procedures. Although SU-AVR several extended indications proven be successful, data on endocarditis remain scarce. The aim study was examine...
Abstract Background In our institution, we developed a modification of the standard implantation technique Perceval sutureless aortic prosthesis (LivaNova, London, United Kingdom) that involves usage snuggers for guiding sutures during valve deployment. The has been described elsewhere. this article, present results initial case series comprising 128 consecutive patients. Methods From September 2016 to June 2018, patients received (mean age 72.2 ± 8.5 years, 66 males). data were...
Redo surgical mitral valve replacement (SMVR) remains the gold standard treatment in patients with a history of surgery presenting recurrent pathologies. Whilst this procedure is demanding, it an inevitable intervention for some indications, such as infective endocarditis, thrombosis, or multivalve procedures. In study, we aim to evaluate our institutional experience SMVR on real-life cohort, identifying factors that contribute poor outcomes whilst avoiding selection bias.Between March 2012...
Abstract Background In the era of transcatheter methods, patients presenting with a pure aortic regurgitation (AR) are not considered eligible for treatment and therefore require another less invasive surgical option. We sought to review our experience sutureless valve replacement (SU-AVR) in symptomatic AR, which until now is contraindication implementation prostheses Europe. Methods Between April 2018 June 2021, 80 consecutive underwent SU-AVR various indications at institution. analyzed...
Surgical management of aortic arch diseases is one the most challenging issues in cardiovascular surgery. The aim this study was to compare outcome after frozen elephant trunk (FET) with conventional (ET) technique.Out a total 551 patients thoracic surgery, we analyzed 70 consecutive patients, who underwent replacement ET or FET technique between 2001 and 2017 our institution. were case-control matched regard such variables as age, sex, presence an acute dissection necessity for concomitant...
We present a modified implantation technique of the Perceval ® sutureless aortic valve (LivaNova, London, United Kingdom) that involves usage snuggers for guiding sutures during deployment.Both limbs each suture are pulled through an elastic tube, which is fixed with Pean clamp, tightens and fixes prosthesis to annulus deployment.This method proved safe useful in over 120 cases.Valve was facilitated need manipulation by assistant or nurse eliminated.
Since the development of endoscopic vision in late 1970s, implementation minimally invasive surgical methods has been rapidly progressing throughout a wide range disciplines, including cardiovascular surgery. The benefits procedures reduction operative trauma and postoperative morbidity, have well-documented compared to open-heart procedures, eventually becoming preferred modality treatment by many centers. Due cost ineffectiveness robotic systems for numerous institutions, new technologies...
Sutureless aortic valve prostheses have proven to provide a significant decrease in procedural, cardiopulmonary bypass and cross-clamp time, leading reduction mortality risk elderly high-risk cohorts. In this study, we sought review our institutional experience on the sutureless replacement (SU-AVR) concomitant mitral (SMVR), comparing combined conventional surgical (SAVR) with SMVR.Between March 2018 July 2022, 114 consecutive patients underwent at institution. We stratified according...
BACKGROUND Overall, life expectancy at the age of 80 has significantly increased in industrialized world and proportion this class undergoing cardiac surgery also grown. In context, we have analyzed a contemporary series octogenarians mitral valve our institution. MATERIAL AND METHODS We performed retrospective analysis 138 consecutive receiving between January 2006 April 2017. Preoperative comorbidities, early mortality, postoperative clinical course, predictors mortality were examined....
Despite the rapid expansion of transcatheter approaches for aortic valve implantation, surgical replacement remains treatment choice in patients presenting with multiple valvular heart disease. We sought to review our clinical experience sutureless (SU-AVR) setting multivalve procedures, addressing postoperative outcomes and technical challenges.Between December 2019 2020, 20 consecutive high-risk at institution underwent SU-AVR concomitant mitral procedure various indications.The mean age...
Background Transcatheter methods have been rapidly evolving to provide an alternative less invasive therapeutic option, mainly because redo patients often present with multiple comorbidities and high operative risk. We sought evaluate compare our experience transapical transcatheter mitral valve replacement (TA-TMVR) conventional in presenting degenerated biological prostheses or failed annuloplasty. Methods material Between March 2012 November 2020, 74 consecutive high-risk underwent...
Abstract Our aim was to analyse the hospital outcome for worldwide largest series of stentless bioroot xenografts (Medtronic Freestyle) as full root replacement in a single centre over period 18 years. Retrospective data analysis performed entire cohort patients undergoing aortic surgery with Medtronic Freestyle valve prosthesis. Logistic regression predictors in-hospital mortality. 971 underwent from 1999–2017, an average age 68.8 ± 10.3y and gender distribution 608:363 (male:female)....